Navigation Links
Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
Date:4/1/2011

ive genotype-1 (GT-1) HCV patients were randomized (1:1:2:2) to receive either:

  • Placebo plus PegIFN/RBV;
  • BI 201335 120mg once-daily (QD) with a three-day LI of PegIFN/RBV;
  • BI 201335 240mg QD with a three-day LI of PegIFN/RBV; or
  • BI 201335 240mg QD plus PegIFN/RBV without LI

  • Patients were given BI 201335 for 24 weeks in combination with PegIFN/RBV, which was given for 24 or 48 weeks. Patients in the two BI 201335 240mg QD groups who achieved extended rapid virological response (eRVR, defined as plasma viral load less than 25 IU/ml at Week four and undetectable at Weeks 8-20), were re-randomized to discontinue PegIFN/RBV at Week 24 or continue PegIFN/RBV to Week 48.Treatment Outcomes in SILEN-C1 (Treatment-Naive Patients)Placebo
    (N=71)120mg
    QD/LI
    (N=69)240mg
    QD/LI
    (N=142)240mg
    QD
    (N=142)eRVR, %

    16

    80

    78

    87SVR, %

    56

    71

    73

    83Breakthrough*, %

    3

    6

    4

    3Relapse**, %

    14

    7

    11

    8*Rebound on treatment with BI 201335

    **Rebound after the end of all treatment Overall SVR rates reached 83 percent in the 240mg QD group (plus current SOC). A three-day lead in with SOC prior to initiation of BI 201335 was seen to reduce responses by 12 percent and 10 percent in 120mg QD/LI and 240mg QD/LI patient groups.  The LI was also associated with higher rates of viral breakthrough.  Of the patients in the 240mg QD dose group who achieved extended rapid viral response (eRVR, defined as plasma viral load less than 25 IU/ml at Week four and Weeks 8-20) and were re-randomized at Week 24, 93 percent achieved SVR with 24 weeks of SOC (PegIFN/RBV) treatment.  

    The most frequent dose-dependent adverse events (AEs) in BI 201335 treatment groups were gastrointestinal disorders, rash or photosensitivity, and jaundice resulting from isolated unconju
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
    3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
    7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
    9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
    10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
    11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... and DUBLIN , Jan. 23, 2015 ... with KRS Global Biotechnology, Inc. for the compounding, packaging and ... for shipment in the United States . ... Outsourcing Facility capable of compounding naltrexone tablets in various strengths ...
    (Date:1/23/2015)... Jan. 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself ... share and grab a foothold in the hydroponic, hemp and ... and a presence in the sector, and recently partnering with ... of hemp and medical marijuana, iMD is committing to bring ...
    (Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
    Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
    ... N.C. , July 23 Sales executives agree that ... process. Yet only 6 percent of district sales managers currently understand ... , , , ... knowledge of health outcomes, evidence based medicine and reimbursement," states an ...
    ... July 23 The North Shore-LIJ Health System Department of ... oropharynx (back of the mouth) to participate in a Phase I clinical ... Subjects must be ... must be unassociated with the human papilloma virus (HPV-negative), or, if it ...
    Cached Medicine Technology:Health Outcomes Data Essential to Biopharmaceutical Sales Process 2Health Outcomes Data Essential to Biopharmaceutical Sales Process 3Study Seeks Volunteers to Measure Safety of Treatment 'Boost' for Patients with Oropharyngeal Cancer 2
    (Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
    (Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
    (Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
    (Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
    (Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
    Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
    ... the pulmonary division at National Jewish Medical and Research Center ... before bedtime and asthma medicines in the late afternoon to ... the fact that body behaviour is not the same at ... the circadian rhythms influences allergy and asthma. "Taking your ...
    ... herself and her new born proud. The mama is the first ... was conceived with a frozen egg and sperm.// ,The ... her chances of having a baby with the conventional method. Apparently, ... hopes of having a baby, something she wanted more than anything ...
    ... decision to adopt much of Federal Government’s preferred model ... and accreditation of training for each of the nine ... said that overall this is great news for the ... there will be nationally consistent standards for registration and ...
    ... in Afghanistan are increasingly suffering from war–related anxiety and ... ,Ontario’s ombudsman Andre Marin had undertaken a recent ... center for treatment of such traumatized children was caught ... bodies unwilling to take financial responsibilities. ,Mr. ...
    ... notices to All India Institute of Medical Sciences (AIIMS) ... filed by a former patient alleging// that the state-run ... from patients undergoing treatment at its cardiac and neuro ... notices Thursday to Venugopal, Mayank Sharma, former senior financial ...
    ... team of UK scientists have undertaken what is described as ... ,Their findings will mark the biggest single leap in the ... opening the door to a new wave of tailored therapies ... a serious illness. ,A coalition of 50 groups, ...
    Cached Medicine News:Health News:COAG Gets It Mostly Right On National Registration 2Health News:Collateral Damage-Children Of Canadian Soldiers Suffer 2Health News:Court Issues Notice to Venugopal Over Fund Irregularities 2Health News:UK Scientists to Reveal Genetic Secrets Behind Serious Illnesses 2
    Two point fixation, tips separated by 13 mm. Each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with thumb catch lock and dull finish....
    ... A simple, effective method for determining color ... reliable data which can be applied to ... The set consists of four trays containing ... caps that have incremental hue variation on ...
    ... Farnsworth 100 Hue Test including MS-Excel scoring template ... Farnsworth 100 Hue Test comes boxed in clear ... the potential for test disruption by holding ... test from Richmond Products includes 93 color discs, ...
    ... modification of the Farnsworth-Munsell 100 Hue Test. It ... the in-depth study of a color vision defect. ... ease or difficulty in distinguishing color differences in ... 15 color reference caps with Munsell notations, plus ...
    Medicine Products: